Incyte Announces Promising New Data on Oncology Candidate at ESMO
ZacksINCY’s INCB123667 data show the candidate’s potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.